Conducting omega-3 clinical trials with cardiovascular outcomes: Proceedings of a workshop held at ISSFAL 2014
Conducting omega-3 clinical trials with cardiovascular outcomes: Proceedings of a workshop held at ISSFAL 2014
In contrast to earlier long-chain (LC) omega-3 (i.e. EPA and DHA) investigations, some recent studies have not demonstrated significant effects of EPA and DHA on cardiovascular disease (CVD) outcomes. The neutral findings may have been due to experimental design issues, such as: maintenance on aggressive cardiovascular drug treatment overshadowing the benefits of LC omega-3s, high background LC omega-3 intake, too few subjects in the study, treatment duration too short, insufficient LC omega-3 dosage, increase in omega-6 fatty acid intake during the study, failure to assess the LC omega-3 status of the subjects prior to and during treatment and lack of clarity concerning which mechanisms were expected to produce benefits. At the 11th ISSFAL Congress, a workshop was held on conducting LC omega-3 clinical trials with cardiovascular outcomes, with the goal of gaining a better understanding concerning aspects of experimental design that should be considered when planning clinical studies related to EPA and DHA and potential cardiovascular benefits.
30-42
Rice, H.B.
c7a99d8d-e38b-4012-80b8-36dae3d9a0da
Bernasconi, A.
c893aff7-987c-471c-b42c-78f831b5da35
Maki, K.C.
31dc99ca-0815-4f79-b19a-644b3518259b
Harris, W.S.
649f3f16-5dbc-480d-8565-3ededb7e0d82
von Schacky, C.
8f8b2761-46cd-44db-8b91-a8c750a8f1a2
Calder, P.C.
1797e54f-378e-4dcb-80a4-3e30018f07a6
April 2016
Rice, H.B.
c7a99d8d-e38b-4012-80b8-36dae3d9a0da
Bernasconi, A.
c893aff7-987c-471c-b42c-78f831b5da35
Maki, K.C.
31dc99ca-0815-4f79-b19a-644b3518259b
Harris, W.S.
649f3f16-5dbc-480d-8565-3ededb7e0d82
von Schacky, C.
8f8b2761-46cd-44db-8b91-a8c750a8f1a2
Calder, P.C.
1797e54f-378e-4dcb-80a4-3e30018f07a6
Rice, H.B., Bernasconi, A., Maki, K.C., Harris, W.S., von Schacky, C. and Calder, P.C.
(2016)
Conducting omega-3 clinical trials with cardiovascular outcomes: Proceedings of a workshop held at ISSFAL 2014.
Prostaglandins, Leukotrienes and Essential Fatty Acids, 107, .
(doi:10.1016/j.plefa.2016.01.003).
(PMID:26858145)
Abstract
In contrast to earlier long-chain (LC) omega-3 (i.e. EPA and DHA) investigations, some recent studies have not demonstrated significant effects of EPA and DHA on cardiovascular disease (CVD) outcomes. The neutral findings may have been due to experimental design issues, such as: maintenance on aggressive cardiovascular drug treatment overshadowing the benefits of LC omega-3s, high background LC omega-3 intake, too few subjects in the study, treatment duration too short, insufficient LC omega-3 dosage, increase in omega-6 fatty acid intake during the study, failure to assess the LC omega-3 status of the subjects prior to and during treatment and lack of clarity concerning which mechanisms were expected to produce benefits. At the 11th ISSFAL Congress, a workshop was held on conducting LC omega-3 clinical trials with cardiovascular outcomes, with the goal of gaining a better understanding concerning aspects of experimental design that should be considered when planning clinical studies related to EPA and DHA and potential cardiovascular benefits.
Text
1-s2.0-S0952327815300132-main.pdf
- Version of Record
More information
Accepted/In Press date: 4 January 2016
e-pub ahead of print date: 25 January 2016
Published date: April 2016
Organisations:
Human Development & Health
Identifiers
Local EPrints ID: 392958
URI: http://eprints.soton.ac.uk/id/eprint/392958
PURE UUID: 4f2f5274-ea91-4d97-afcd-34de8a0c7622
Catalogue record
Date deposited: 19 Apr 2016 11:09
Last modified: 15 Mar 2024 02:50
Export record
Altmetrics
Contributors
Author:
H.B. Rice
Author:
A. Bernasconi
Author:
K.C. Maki
Author:
W.S. Harris
Author:
C. von Schacky
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics
